That's way too strong a negative response. First, it would take at least 10 years for something to come out of this and into the clinical setting. Second, it might not jump all of the hurdles along the path to the clinic.
Tissue Therapies has a developed product a long way from the lab yet it still requires a few more years of hurdle jumping. Still hopeful that it will get there though. All will depend on the Phase 2.
BTW, the reg briefing hookup was excellent; it boosted my confidence that they now know what they should be doing and are doing it.
- Forums
- ASX - By Stock
- TIS
- Ann: FDA Regulatory Progress Update - Conference Call Details
Ann: FDA Regulatory Progress Update - Conference Call Details, page-6
Featured News
Add TIS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
NXD
NEXTED GROUP LIMITED
Nick Poll, Managing Director
Nick Poll
Managing Director
SPONSORED BY The Market Online